New stock first day | (02546) First listed in the morning with a high opening of 139.47% The company is Xizang Mineral Development.
Zhixu Mining (02546) made its debut on the stock market, with an announcement indicating an offer price of HK$4.51 per share. A total of 121.952 million shares were issued, with a trading unit of 1000 shares. The net proceeds amounted to approximately HK$ 4.951 billion. As of the time of writing, the stock price has risen by 139.47% to HK$10.8, with a trading volume of HK$1.5 billion.
Debut on Stock Exchange with an announcement showing that the price per share is 4.51 Hong Kong dollars, issuing a total of 121.952 million shares, with a minimum trading unit of 1000 shares, resulting in a net amount of approximately 4.951 billion Hong Kong dollars. As of the time of writing, the stock has risen by 139.47% to 10.8 Hong Kong dollars, with a trading volume of 1.5 billion Hong Kong dollars.
According to public information, the company is a mining company that focuses on zinc, lead, and copper exploration, mining, concentrate production, and sales in Tibet, China. According to data from the Shanghai Nonferrous Metal Network, based on the average annual production of zinc concentrate, lead concentrate, and copper concentrate in Tibet in 2024, the group ranks fifth, fourth, and fifth, respectively.
In 2024, the company accounted for 11.1% of the total zinc concentrate production, 4.2% of the total lead concentrate production, and 0.1% of the total copper concentrate production in Tibet. The production of lead and copper concentrates in Tibet is dominated by leading companies. In 2024, the two largest companies in Tibet accounted for 36.1% and 31.6% of the total market share in lead concentrate production, respectively; the two largest companies in Tibet also accounted for 44.2% and 42.3% of the total market share in copper concentrate production in Tibet, respectively.
Related Articles

CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.






